ICICI Securities recommends buying Cipla with ₹1,610 target after Q2

Business Oct 28, 2026

ICICI Securities thinks Cipla is worth a look right now, recommending investors buy the pharma giant's shares with a target price of ₹1,610.

This follows Cipla's solid Q2 performance (even after last year's big sales boost from gRevlimid), showing the company can keep up momentum.

Cipla US sales hit $172 million

Cipla's US sales jumped 6.2% this quarter to $172 million, thanks to new respiratory and peptide products hitting the market.

With recent approvals for gVentolin and gAdvair, they're aiming even higher, targeting $250 million in US sales per quarter by early next year.

Even with some earnings estimates trimmed, Cipla expects its profit margins to stay healthy at around 18.5% to 20%.